Examining the Complex Mismatch Negativity in Early Phase Psychosis Using the Dual Rule Paradigm

Area of Science:

• Neuroscience
• Psychiatry
• Biomarkers

Background:

• Simple mismatch negativity (MMN) from electroencephalography (EEG) is studied as a biomarker for psychotic illness.
• MMN deficits are inconsistently reported in early psychotic illness, questioning its sensitivity.
• Complex mismatch negativity (cMMN) is proposed as a more sensitive auditory cortex function marker for illness vulnerability.

Purpose of the Study:

• To investigate the utility of a novel dual rule cMMN paradigm in individuals with early phase psychosis (EPP).
• To explore the sensitivity of cMMN as a potential biomarker for psychosis.
• To examine relationships between cMMN, symptom severity, and functioning in EPP.

Main Methods:

• A dual rule paradigm was used to elicit cMMN in 14 individuals with EPP and 15 healthy controls (HC).
• EEG data was analyzed to compare cMMN amplitudes between groups.
• Correlations between cMMN, symptom severity, and functioning were assessed.

Main Results:

• Reduced cMMN amplitudes were observed in the EPP group compared to HC (p = .017).
• Large effect sizes (Hedges' g = 0.96) supported the significant difference.
• The dual rule cMMN paradigm demonstrated potential for eliciting subtle neurofunctional changes.

Conclusions:

• The dual rule cMMN paradigm shows promise for identifying early psychosis biomarkers.
• cMMN may be a more sensitive measure of auditory cortex dysfunction in early illness stages.
• Further research is warranted to validate cMMN as a biomarker for psychosis.